Date: 2016-07-14
Type of information: Collaboration agreement
Compound:
Company: F-Star (UK) Christian Doppler (CD) Laboratory for Innovative Immunotherapeutics (Austria)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On July 14, 2016, F-star, a biopharmaceutical company developing novel bispecific antibodies with a focus on immuno-oncology, announced the extension of a multi-year collaboration and funding arrangement with the newly opened Christian Doppler (CD) Laboratory for Innovative Immunotherapeutics at BOKU, the University of Natural Resources and Life Sciences in Vienna. The collaboration allows F-star to explore additional applications of its Modular Antibody Technology with options to intellectual property arising from work in the lab during this period. The collaboration is jointly funded by the BMWFW (Austrian Federal Ministry of Science, Research and Economy) and F-star Biotechnology Ltd.
The CD Laboratory and F-star seek to progress the understanding of the design, development and unique biology of antibody and antibody-based therapeutics by harnessing the ability of the human immune system to attack diseased cells, such as cancer cells that usually remain undetected.
A first approach will be to enable the immune system to recognise and differentiate between cancer and healthy cells then trigger the targeted death of the malignant cells. Another scope investigated will be to enhance the innate disease targeting ability of the immune system by blocking one of the tumour’s defence mechanisms.
Financial terms:
Latest news:
